Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aspirin for Preventing Barrett's Esophagus Recurrence After Radiofrequency Ablation
NCT02521285Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Jan 2016
- Primary completion
- Jun 2019
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
A Phase 2 trial of aspirin in Barrett's esophagus, sponsored by National Cancer Institute. Started Jan 2016; status: active, not recruiting.
02
Drugs
aspirin
03
Conditions
Barrett's esophagus
Beyond the preview
Go deeper on NCT02521285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02521285.